Search: onr:"swepub:oai:DiVA.org:liu-52881" >
Rationale and desig...
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
-
- Schwartz, Gregory G (author)
- VA Med Ctr, Cardiol Sect 111B, Denver, CO 80220 USA
-
- Olsson, Anders (author)
- Östergötlands Läns Landsting,Linköpings universitet,Internmedicin,Hälsouniversitetet,Endokrin- och magtarmmedicinska kliniken US
-
- Ballantyne, Christie M (author)
- Baylor Coll Med, Houston, TX 77030 USA
-
show more...
-
- Barter, Phillip J (author)
- Heart Res Inst, Sydney, NSW, Australia
-
- Holme, Ingar M (author)
- Oslo Univ Hosp, Oslo, Norway
-
- Kallend, David (author)
- F Hoffmann La Roche and Co Ltd, CH-4002 Basel, Switzerland
-
- Leiter, Lawrence A (author)
- Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada
-
- Leitersdorf, Eran (author)
- Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel
-
- McMurray, John J V (author)
- Univ Glasgow, Cardiovasc Res Ctr, British Heart Fdn, Glasgow G12 8QQ, Lanark, Scotland
-
- Shah, Prediman K (author)
- Cedars-Sinai Medical Center, Los Angeles, CA
-
- Tardif, Jean-Claude (author)
- Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada
-
- Chaitman, Bernard R (author)
- Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
-
- Duttlinger-Maddux, Regina (author)
- F Hoffmann La Roche and Co Ltd, CH-4002 Basel, Switzerland
-
- Mathieson, John (author)
- F Hoffmann La Roche and Co Ltd, CH-4002 Basel, Switzerland
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2009
- 2009
- English.
-
In: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 158:6, s. 896-U34
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Background Despite contemporary therapies for acute coronary syndrome (ACS), morbidity and mortality remain high. Low levels of high-density lipoprotein (HDL) cholesterol are common among patients with ACS and may contribute to ongoing risk. Strategies that raise levels of HDL cholesterol, such as inhibition of cholesterol ester transfer protein (CETP), might reduce risk after ACS. Dal-OUTCOMES is a multicenter, randomized, double-blind, placebo-controlled trial designed to test the hypothesis that CETP inhibition with dalcetrapib reduces cardiovascular morbidity and mortality in patients with recent ACS. Design The study will randomize approximately 15,600 patients to receive daily doses of dalcetrapib 600 mg or matching placebo, beginning 4 to 12 weeks after an index ACS event. There are no prespecified boundaries for HDL cholesterol levels at entry. Other elements of care, including management of low-density lipoprotein cholesterol, are to follow best evidence-based practice. The primary efficacy measure is time to first occurrence of coronary heart disease death, nonfatal acute myocardial infarction, unstable angina requiring hospital admission, resuscitated cardiac arrest, or atherothrombotic stroke. The trial will continue until 1,600 primary end point events have occurred, all evaluable subjects have been followed for at least 2 years, and 80% of evaluable subjects have been followed for at least 2.5 years. Summary Dal-OUTCOMES will determine whether CETP inhibition with dalcetrapib, added to current evidence-based care, reduces cardiovascular morbidity and mortality after ACS.
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Schwartz, Gregor ...
-
Olsson, Anders
-
Ballantyne, Chri ...
-
Barter, Phillip ...
-
Holme, Ingar M
-
Kallend, David
-
show more...
-
Leiter, Lawrence ...
-
Leitersdorf, Era ...
-
McMurray, John J ...
-
Shah, Prediman K
-
Tardif, Jean-Cla ...
-
Chaitman, Bernar ...
-
Duttlinger-Maddu ...
-
Mathieson, John
-
show less...
- Articles in the publication
-
American Heart J ...
- By the university
-
Linköping University
-
Karolinska Institutet